Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- Conditions
- Non Small Cell Lung CancerEpidermal Growth Factor Receptor Gene MutationStage III Lung CancerStage IV Lung Cancer
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 538
- Registration Number
- NCT06538038
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mercy Clinic Fort Smith Communities, Fort Smith, Arkansas, United States
🇺🇸Mercy Research, Fort Smith, Arkansas, United States
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
- Conditions
- Pleural MesotheliomaMesotheliomaMalignant Pleural Mesothelioma
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 214
- Registration Number
- NCT04334759
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 181
- Registration Number
- NCT03836209
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of California, San Francisco-Fresno (University Oncology Associates), Clovis, California, United States
🇺🇸UCLA, Los Angeles, California, United States
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 33
- Registration Number
- NCT03834688
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸St. Joseph Mercy Hospital Cancer Care Center, Ann Arbor, Michigan, United States
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT03532451
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT03323151
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
- Conditions
- Follicular LymphomaNon-Hodgkin's Lymphoma FollicularNon-Hodgkin's Lymphoma, Adult High Grade
- Interventions
- Drug: Induction VenetoclaxDrug: Maintenance Venetoclax
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 56
- Registration Number
- NCT03113422
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 55
- Registration Number
- NCT02899195
- Locations
- 🇺🇸
University San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
- Conditions
- Squamous Cell Carcinoma of the Lung
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 13
- Registration Number
- NCT02713828
- Locations
- 🇺🇸
University of Miami Hospital, Miami, Florida, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Ochsner Medical Center, New Orleans, Louisiana, United States
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 74
- Registration Number
- NCT02181634
- Locations
- 🇺🇸
Colorado Cancer Research Program, Denver, Colorado, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States